Headache and Migraine

The professor of neurology at both the University of California San Francisco and King’s College, London, spoke about the results from a phase 2b/3 study evaluating atogepant for prevention of migraine.

Neurology News Network for the week ending June 8, 2019.

Emgality (galcanezumab-gnlm) is the first FDA-approved drug that reduces the frequency of headache attacks.

The program director of neurology at Zucker School of Medicine, Northwell Health, reviewed the contributions of neurologist S. Weir Mitchell, MD, and how today’s neurologists can gain insights for their own practice from Mitchell’s complicated history.

Galcanezumab, an anti-CGRP antibody, is now the first approved therapy for the treatment of episodic cluster headache just 9 months after receiving approval for the preventive treatment of migraine.

Neurology News Network for the week ending June 1, 2019.

Results of a pooled analysis of 3 clinical trials suggest that the magnitude of fingolimod’s treatment effect in MS is not affected by the presence of migraine or headache in patients.

A new tool to add to your armamentarium?

To kick off Migraine and Headache Awareness Month, the latest findings reported here may influence your approaches to diagnosis, treatment, and prevention and help you keep your patients informed.

This device, which is being prepared to launch in the US market later this year, is an alternative treatment option for acute migraine.